No Data
Insider decrases its stake in BuySell Technologies(7685.JP) to 59.12%
On Oct 22, 株式会社ミダスキャピタル submitted the Change Report to Ministry of Finance. The report shows that 株式会社ミダスキャピタル decreased their holdings in $BuySell Technologies(7685.JP)$, with their joint
BuySell Technologies Remains Optimistic Amid Regional Challenges
Stocks that moved the previous day part1: Ryomo Systems, Sansan, Disco, etc.
Obtained a domestic patent related to the method for predicting the efficacy of rheumatoid arthritis treatment drugs and evaluating the activity of rheumatoid arthritis.
Stocks that moved the previous day part1 Last One Mile, BUYSELL, gan ltd, etc
Brand Name <Code> 17th closing price ⇒ Previous day comparison BBSec <4398> 1490 +41 Announced change in shareholder return policy. Tokai Software <4430> 1273 +41 Subsidiarization of software development company. Pacific Semes <5233> 3447 +183 Announcement of share buyback up to 5.18% of issued shares. GlobalW <3936> 158 -7 Dislike of margin trading regulations. Last One Mile <9252> 3090 +381 Postponed the announcement of the fiscal year ending August 24, which was previously delayed.
Active and newly established stocks in the afternoon session.
*BBSec <4398> announced a change in the shareholder return policy with +41 shares. *Tokai Soft <4430> subsidiary of software development company with +41 shares. *Pacific Sem <5233> announced a share buyback with a maximum of 5.18% of the outstanding shares. *Global W <3936> -7 dislikes the margin trading regulations. *Last One Mile <9252> postponed announcement of the 24th fiscal year ending in August confirmation date to October 18th.
Emerging Markets Digest: Deere & Co soaring, BUYSELL plummeting
<219A> Heartseed 1515 rebounds by +51. Company announced an upward revision of financial estimates for the fiscal year ending October 24, with revenue increasing from 15.3 billion yen to 0.874 billion yen (an increase of 470.2%), and operating loss expected to decrease from a deficit of 1.965 billion yen to a deficit of 105.9 billion yen, narrowing the loss margin. Under an exclusive technical partnership and licensing agreement targeting the global market with novo-nordisk a/s, a major global pharmaceutical company, the development milestone expected for the fiscal year ending October 25 has been anticipated as of January 24.
No Data
No Data